Comparison of ibrutinib and idelalisib plus rituximab in real‐life relapsed/resistant chronic lymphocytic leukemia casesFortunato Morabito, Massimo Gentile, Luca Laurenti et al.|European Journal Of Haematology|2020Cited by 7
Mutant p53K120R expression enables a partial capacity to modulate metabolismPaola Monti, Paola Menichini|Frontiers in Genetics|2022Cited by 7
Effectiveness of ibrutinib as first‐line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab‐bendamustine: Results of study on 486 cases outside clinical trialsFortunato Morabito, Massimo Gentile, Giovanni Tripepi et al.|American Journal of Hematology|2021Cited by 3